0001062993-23-006867.txt : 20230314 0001062993-23-006867.hdr.sgml : 20230314 20230314182603 ACCESSION NUMBER: 0001062993-23-006867 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230313 FILED AS OF DATE: 20230314 DATE AS OF CHANGE: 20230314 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Luly Jay R. CENTRAL INDEX KEY: 0001571211 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35839 FILM NUMBER: 23732506 MAIL ADDRESS: STREET 1: C/O ENANTA PHARMACEUTICALS, INC. STREET 2: 500 ARSENAL STREET CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ENANTA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001177648 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 500 ARSENAL STREET CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617 607 0800 MAIL ADDRESS: STREET 1: 500 ARSENAL STREET CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0306 4 2023-03-13 0001177648 ENANTA PHARMACEUTICALS INC ENTA 0001571211 Luly Jay R. C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472 1 1 0 0 President and CEO Common Stock 2023-03-13 4 M 0 27912 14 A 847722 D Common Stock 2023-03-13 4 S 0 10697 44.81 D 837025 D Common Stock 2023-03-13 4 S 0 15649 45.31 D 821376 D Common Stock 2023-03-13 4 S 0 1566 46.13 D 819810 D Stock Option (Right to Buy) 14.00 2023-03-13 4 M 0 27912 0 D 2023-03-21 Common Stock 27912 0 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2022. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.39 to $44.99, inclusive. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.00 to $46.54, inclusive. On March 21, 2013, the reporting person was granted an option to purchase 83,526 shares of common stock, half of which became exercisable upon the achievement of several clinical milestones during the four-year performance period after the date of grant. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 4 above. /s/ Nathaniel S. Gardiner as attorney-in-fact 2023-03-14